SemaxFocus, cognition, and neuro recovery interest — with a real clinical path.
A seven-amino-acid ACTH(4–10) analog studied for stroke recovery, migraine, and trigeminal neuralgia.
Semax is the peptide people want when focus, cognitive edge, and neurological recovery matter. It is registered as a drug in Russia and was recommended for U.S. compounding in July 2026. Join the waitlist for first access when pharmacy-sourced Semax can be evaluated through AlphaMD.
By joining, you opt in to launch and marketing email about Semax from AlphaMD. You can unsubscribe at any time.
- U.S. compounding pharmacies only
- Discreet shipping
- 100% confidential
Why Semax Gets Attention
More human exposure than the other peptides here — and a clear U.S. path still forming.
Semax is a synthetic heptapeptide built from the 4–10 fragment of adrenocorticotropic hormone with a short stabilizing tail. The modification preserves the neurological activity researchers wanted while dropping ACTH’s hormonal effects on the adrenal glands and skin pigmentation.
It is registered as a drug in Russia and sold there as nasal drops for stroke recovery and cognitive complaints. That foreign registration is real — it is not an FDA approval. U.S. reviewers still judged the dossier insufficient for the three uses they examined in 2026, partly because some supporting studies lacked verified English translations.
What exists in English includes functional MRI work showing changes in resting-state connectivity in healthy adults, animal BDNF/TrkB signaling data, and small clinical series for stroke, migraine, and trigeminal neuralgia. In July 2026 an advisory committee recommended compounding inclusion 8–5 with one abstention. The waitlist is first access when a U.S. pharmacy can lawfully produce and test it.
Where Semax Stands Today
- Recommended for compoundingAdvisory vote 8–5 (1 abstention), July 24, 2026
- FDA scientists advised against itAgency staff recommended no; the advisory committee voted yes 8–5
- Evidence still thin for reviewed usesFDA found the data inadequate for cerebral ischemia, migraine, and trigeminal neuralgia
- Registered in Russia, not hereA foreign drug registration is not an FDA approval
- Unsettled in tested sportNot named by WADA, and complicated by its Russian drug status
- Prescription-only at launchProvider evaluation and intake required — no direct purchase
Russian registration means real people have taken Semax for years. It does not replace a U.S. pharmacy path with lot-level testing — that is what the waitlist is for.
What You May Get From Semax
The focus and neuro upsides people want — including where early human work was encouraging and where it was not.
Brain network activity
A functional MRI study in 24 healthy adults found measurable changes in resting-state connectivity, with a second study covering 52 participants — real human imaging data behind the focus interest.
Small human studiesBDNF signaling
In rats, Semax increased brain-derived neurotrophic factor and its receptor TrkB — the mechanism behind most cognitive claims made for it.
Animal dataStroke recovery
The primary use the FDA reviewed. Published stroke work is a small abstract comparing 30 patients with 80 controls without methodology anyone can fully assess — interest is high; evidence is still thin.
Weak human dataMigraine
One uncontrolled study of 12 people, 4 of whom saw migraines resolve. Early signal only — not separable from the natural course without a control group.
Weak human dataTrigeminal neuralgia
An uncontrolled study found no meaningful improvement in typical trigeminal neuralgia. Included because fit criteria should match the full research picture.
Studied, not supportedWho Semax May Be A Fit For
A provider makes this call with you after reviewing your history and medication list.
- Recovering from a neurological event with a rehab plan in place — as an addition to that plan, never as a substitute for it.
- Living with migraine that standard preventives have not controlled, and open to an option with early human signals still being sorted out.
- Not taking an anticoagulant or antiplatelet — the risks section covers the bleeding flag the FDA raised.
- Interested in cognition and neuroscience, with realistic expectations about what small imaging studies show.
- Already an AlphaMD member whose full medication list is already on file — what makes the bleeding question answerable.
Who Should Skip It
Practical fit filters — a provider will decline when these apply.
- You are having stroke symptoms right now. Call 911. Nothing on this page substitutes for emergency stroke care.
- You take an anticoagulant or antiplatelet. FDA flagged possible antithrombotic activity, which raises bleeding risk — same with a bleeding disorder, recent surgery, or hemorrhagic stroke history.
- You take prescription stimulants. A rodent study found Semax enhanced amphetamine-related dopamine release; the human interaction has never been studied.
- You are buying nasal drops online. The only adverse-event report the FDA holds involves exactly that unverified channel.
- You're pregnant, nursing, or trying to conceive. No reproductive or developmental safety data exists.
What To Know About Risks
More people have used Semax than the other peptides here. That also makes the known safety flags more useful — here they are, plainly.
Bleeding risk
FDA flagged possible antithrombotic and anticoagulant activity. For anyone on blood thinners, with a bleeding disorder, recently out of surgery, or with hemorrhagic stroke history, that is a specific concern.
The adverse-event report on file
Through December 3, 2025, FDA held a single report: a consumer who used online Semax nasal drops developed eye pain and burning, was hospitalized, and whose pain had not resolved. The product was never verified — which is the gray-market point.
Interaction with stimulants
A rodent study showed enhanced amphetamine-related dopamine release. What that means for prescription stimulants has not been studied in a person.
Evidence hard to fully audit outside Russia
Several supporting studies were Russian-language only or lacked verified translations, so FDA reviewers could not assess them properly.
Limited monitored long-term data for U.S. clinicians
Years of use in one country is not the same as published, monitored follow-up a U.S. clinician can cite in detail.
Unverified online product
The single documented harm here came from an unverified internet product. Pharmacy identity testing is the reason to wait for a U.S. launch path.
Pharmacy-Sourced Beats Gray-Market Guesswork
Semax exists as a regulated pharmacy product in Russia, which makes the U.S. online market especially confusing. What arrives in a U.S. mailbox is not that pharmacy product — and the adverse-event report on file came through exactly that channel.
Gray-market vials
- Peptide content well under — or over — what the label claims
- Bacterial endotoxin from non-sterile production — a fever and sepsis risk you inject directly
- Residual synthesis solvents, heavy metals, and truncated peptide fragments
- Certificates of analysis that are copied, expired, or for an entirely different lot
- No prescriber, no recall path, and no one accountable if you're harmed
A U.S. compounding pharmacy
- State-licensed, FDA-inspected facility working from a real prescription
- Sterile compounding standards for anything injected, with documented process controls
- Third-party potency, sterility, and endotoxin testing tied to your specific lot
- A provider who sets your dose, reviews your labs, and owns follow-up
- Traceability — if a lot is bad, it can be found, pulled, and reported
When Semax launches with AlphaMD, members get a U.S. pharmacy that can document identity, sterility, and potency — after a provider evaluation.
Educational Resources
Deeper reading on what Semax is, what Russian registration means, and why sourcing decides most of the risk.
Semax benefits, risks, and side effects: what you need to know
The long-form deep dive: the ACTH relationship, imaging studies, bleeding-risk flag, and why a foreign registration is not an approval.
The FDA reviewed seven popular peptides. Here is what each one may do.
BPC-157, KPV, TB-500, MOTs-c, DSIP, Semax, and Epitalon side by side — reviewed uses, vote counts, and how far the evidence goes.
Are your peptides even real? Why 1 in 5 tested vials came back mislabeled
What third-party assays keep finding inside gray-market products — wrong potency, wrong sequence, and mismatched certificates.
Frequently Asked Questions
Still deciding? Message the team — you don't need to be a member to ask.
Ask a QuestionFirst access when pharmacy-compounded Semax can be offered through AlphaMD — provider evaluation, intake, and product from a U.S. compounding pharmacy with lot-level testing — not an unverified online dropper bottle.
In July 2026 an FDA advisory committee recommended Semax for the 503A bulk-substances list. Final rulemaking still has to finish. Once a pharmacy AlphaMD trusts can lawfully produce and test it, the waitlist gets the email that week.
Not yet. Nothing on this page is for sale. Online nasal drops are not the same as a U.S. pharmacy-compounded product — and the FDA adverse-event report came from that unverified channel.
It means a regulator elsewhere permitted sale and real people have taken it for years. It does not mean the FDA reviewed the same dossier and agreed. In 2026 U.S. reviewers still found the evidence insufficient for every use they examined.
This is a flagged risk. FDA noted possible antithrombotic activity. Anyone on an anticoagulant or antiplatelet, with a bleeding disorder, recently out of surgery, or with hemorrhagic stroke history is excluded here. Bring your complete medication list to any consult.
It is the use FDA reviewed most closely, and reviewers concluded the evidence did not support it yet. If a stroke is happening now, call 911 — nothing should delay emergency care.
Yes — more than for the other five peptides here. Two fMRI studies showed measurable brain-connectivity changes. Clinical series are still small and mostly uncontrolled; trigeminal neuralgia work did not show meaningful improvement.
Semax is not named on the WADA Prohibited List, which is not the same as cleared. The non-approved substances class can still reach it. Confirm with your anti-doping organization before use.
Pricing is not set until a supplier is locked. When it is, it will be published the same way TRT pricing is: one clear number, per month.
Explore Other Peptides
Five more on the same July 2026 compounding slate — join each waitlist for first access when they launch.
Get First Access to Semax
Join the waitlist for pharmacy-sourced Semax through AlphaMD — provider evaluation, tested product, discreet shipping. Already a member? Bring peptides up at your next visit or book a consult to get intake done early.
By joining, you opt in to launch and marketing email about Semax from AlphaMD. You can unsubscribe at any time.
No insurance needed · Cancel anytime · 100% confidential
Legal Disclaimer
Semax is not an FDA-approved drug and is not currently available for sale or prescription through AlphaMD. Nothing on this page is an offer to sell, and nothing here is medical advice. Statements about potential benefits describe published preclinical research and small, largely uncontrolled human studies and are not claims about outcomes for any individual. Peptide therapy, if and when offered, will require a consultation with a licensed medical professional, a completed medical intake, and appropriate laboratory testing; it is not appropriate for everyone. Semax is not named on the World Anti-Doping Agency Prohibited List, but the List's non-approved substances class is a catch-all that can still reach substances lacking regulatory approval; athletes subject to testing should confirm status with their anti-doping organization before use.
Medical services are provided by independent, licensed providers through AlphaMD's affiliated professional practices. AlphaMD provides administrative and technology services and does not practice medicine.